Explore the vast range of titles available.

Greenhouse and field experiments were conducted to evaluate the potential for antagonistic or synergistic interactions from tank mixtures of glyphosate plus a selective herbicide applied postemergence. In the greenhouse, glyphosate at 420 g ae ha−1 plus 28% liquid urea-ammonium nitrate (28% UAN) provided at least 89% control of common lambsquarters and common ragweed. Glyphosate at 1,680 g ha−1 plus 28% UAN provided less than 81% control of velvetleaf and less than 75% control of ivyleaf morningglory. Tank mixing bentazon at 1,120 g ai ha−1 with glyphosate at 420 g ha−1 synergistically increased control of velvetleaf. Tank mixtures of glyphosate plus a selective herbicide were predominately additive in control of common lambsquarters, common ragweed, and velvetleaf. Several tank mix combinations of chlorimuron or imazethapyr plus glyphosate plus 28% UAN were antagonistic in control of ivyleaf morningglory. In the field, glyphosate at 840 g ha−1 plus 28% UAN provided at least 88% control of common lambsquarters and velvetleaf in 1994. However, glyphosate at 840 g ha−1 plus 28% UAN provided only 60% control of velvetleaf in 1995. Tank-mixing bentazon or CGA-248757 with glyphosate at 420 g ha−1 increased velvetleaf and common lambsquarters control in 1995. In general, adding chlorimuron, imazethapyr, or thifensulfuron to glyphosate plus 28% UAN did not increase control of common lambsquarters or velvetleaf. Tank mixing imazethapyr with glyphosate plus 28% UAN antagonized velvetleaf control in 1994 and in 1995. The tank mixture of thifensulfuron at 2 g ha−1 plus glyphosate at 420 g ha−1 plus 28% UAN increased soybean injury in the field in 1994. However, tank mixing chlorimuron, imazethapyr, or thifensulfuron with glyphosate plus 28% UAN did not increase soybean injury in the greenhouse or in the field in 1995.

Vaccination against SARS-CoV-2 has the potential to significantly reduce transmission and COVID-19 morbidity and mortality. The relative importance of vaccination strategies and nonpharmaceutical interventions (NPIs) is not well understood. To assess the association of simulated COVID-19 vaccine efficacy and coverage scenarios with and without NPIs with infections, hospitalizations, and deaths. An established agent-based decision analytical model was used to simulate COVID-19 transmission and progression from March 24, 2020, to September 23, 2021. The model simulated COVID-19 spread in North Carolina, a US state of 10.5 million people. A network of 1 017 720 agents was constructed from US Census data to represent the statewide population. Scenarios of vaccine efficacy (50% and 90%), vaccine coverage (25%, 50%, and 75% at the end of a 6-month distribution period), and NPIs (reduced mobility, school closings, and use of face masks) maintained and removed during vaccine distribution. Risks of infection from the start of vaccine distribution and risk differences comparing scenarios. Outcome means and SDs were calculated across replications. In the worst-case vaccination scenario (50% efficacy, 25% coverage), a mean (SD) of 2 231 134 (117 867) new infections occurred after vaccination began with NPIs removed, and a mean (SD) of 799 949 (60 279) new infections occurred with NPIs maintained during 11 months. In contrast, in the best-case scenario (90% efficacy, 75% coverage), a mean (SD) of 527 409 (40 637) new infections occurred with NPIs removed and a mean (SD) of 450 575 (32 716) new infections occurred with NPIs maintained. With NPIs removed, lower efficacy (50%) and higher coverage (75%) reduced infection risk by a greater magnitude than higher efficacy (90%) and lower coverage (25%) compared with the worst-case scenario (mean [SD] absolute risk reduction, 13% [1%] and 8% [1%], respectively). Simulation outcomes suggest that removing NPIs while vaccines are distributed may result in substantial increases in infections, hospitalizations, and deaths. Furthermore, as NPIs are removed, higher vaccination coverage with less efficacious vaccines can contribute to a larger reduction in risk of SARS-CoV-2 infection compared with more efficacious vaccines at lower coverage. These findings highlight the need for well-resourced and coordinated efforts to achieve high vaccine coverage and continued adherence to NPIs before many prepandemic activities can be resumed.